Search - tctmd.com

Displaying 101 - 120 of 156

Sort: Relevancy | Date

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Daily News

Most Stable Angina Patients Not Taking First-line Meds

Shelley Wood

June 18, 2020

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Daily News

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

Shelley Wood

February 14, 2020

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Caitlin E. Cox

February 07, 2020

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

News Daily News

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

L.A. McKeown

June 25, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Daily News

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

L.A. McKeown

April 17, 2019

News Daily News

Digital Tools Show Promise for Helping STEMI and NSTEMI Patients Avoid Readmission

L.A. McKeown

April 09, 2019

News Daily News

Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD

Lucy Hicks

February 15, 2019

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

News Daily News

Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60%

Michael O'Riordan

October 25, 2018

Advertisement

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Most Stable Angina Patients Not Taking First-line Meds

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

Digital Tools Show Promise for Helping STEMI and NSTEMI Patients Avoid Readmission

Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60%

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content